Q3 EPS Estimate for Tandem Diabetes Care Raised by Analyst

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) – Analysts at Leerink Partnrs boosted their Q3 2024 EPS estimates for shares of Tandem Diabetes Care in a research report issued to clients and investors on Tuesday, October 15th. Leerink Partnrs analyst M. Kratky now forecasts that the medical device company will post earnings of ($0.44) per share for the quarter, up from their previous forecast of ($0.45). The consensus estimate for Tandem Diabetes Care’s current full-year earnings is ($1.76) per share. Leerink Partnrs also issued estimates for Tandem Diabetes Care’s FY2024 earnings at ($1.71) EPS, Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.25) EPS, Q3 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.02) EPS, FY2025 earnings at ($0.81) EPS and FY2026 earnings at ($0.33) EPS.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings data on Thursday, August 1st. The medical device company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.07. Tandem Diabetes Care had a negative return on equity of 41.54% and a negative net margin of 17.15%. The business had revenue of $221.90 million for the quarter, compared to analyst estimates of $205.63 million. During the same quarter last year, the company earned ($0.30) earnings per share. The business’s revenue for the quarter was up 13.3% compared to the same quarter last year.

A number of other equities analysts also recently commented on the company. Wells Fargo & Company raised their price objective on Tandem Diabetes Care from $50.00 to $55.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Robert W. Baird increased their price objective on shares of Tandem Diabetes Care from $36.00 to $39.00 and gave the stock a “neutral” rating in a research report on Friday, August 2nd. Piper Sandler reaffirmed an “overweight” rating and set a $55.00 price target (up from $50.00) on shares of Tandem Diabetes Care in a research report on Friday, August 2nd. The Goldman Sachs Group assumed coverage on Tandem Diabetes Care in a research note on Friday, October 4th. They issued a “neutral” rating and a $46.00 target price for the company. Finally, UBS Group raised Tandem Diabetes Care to a “hold” rating in a research report on Friday, August 2nd. Five investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $55.13.

Tandem Diabetes Care Trading Up 1.5 %

NASDAQ TNDM opened at $35.34 on Friday. The company has a market cap of $2.31 billion, a P/E ratio of -16.91 and a beta of 1.33. Tandem Diabetes Care has a 12 month low of $13.82 and a 12 month high of $53.69. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.05 and a quick ratio of 2.38. The company has a 50-day moving average of $41.98 and a 200-day moving average of $41.85.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TNDM. BNP Paribas Financial Markets lifted its stake in Tandem Diabetes Care by 1,481.5% in the first quarter. BNP Paribas Financial Markets now owns 145,812 shares of the medical device company’s stock valued at $5,163,000 after buying an additional 136,592 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Tandem Diabetes Care during the 1st quarter valued at about $540,000. Vanguard Group Inc. grew its position in Tandem Diabetes Care by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 7,052,570 shares of the medical device company’s stock worth $249,732,000 after purchasing an additional 30,664 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Tandem Diabetes Care in the first quarter valued at approximately $5,227,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Tandem Diabetes Care in the first quarter valued at approximately $710,000.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.